Antidiabetic drugs influence molecular mechanisms in prostate cancer

References

• Jemal A. Global burden of cancer: opportunities for prevention. Lancet. 2012 Nov 24;380(9856):1797–1799. doi:10.1016/S0140-6736(12)61688-2.
   PubMed Web of Science ®Google Scholar
• Vijan S. Type 2 diabetes. Ann Intern Med. 2010 Mar 2;152(5):ITC31–15. doi:10.7326/0003-4819-152-5-201003020-01003.
   PubMedGoogle Scholar
• Bailey CJ, Turner RC. Metformin. N Engl J Med. 1996 Feb 29;334(9):574–579. doi:10.1056/NEJM199602293340906.
   PubMed Web of Science ®Google Scholar
• Cannata D, Fierz Y, Vijayakumar A, LeRoith D. Type 2 diabetes and cancer: what is the connection? Mt Sinai J Med. 2010 Mar;77(2):197–213. doi:10.1002/msj.20167.
   PubMedGoogle Scholar
• Vallianou NG, Evangelopoulos A, Kazazis C. Metformin and cancer. Rev Diabet Stud. 2013;10(4):228–235. doi:10.1900/RDS.2013.10.228.
   PubMedGoogle Scholar
• Decensi A, Puntoni M, Goodwin P, Cazzaniga M, Gennari A, Bonanni B, Gandini S. Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res (Phila). 2010 Nov;3(11):1451–1461. doi:10.1158/1940-6207.CAPR-10-0157.
   PubMed Web of Science ®Google Scholar
• Clements A, Gao B, Yeap SH, Wong MK, Ali SS, Gurney H. Metformin in prostate cancer: two for the price of one. Ann Oncol. 2011 Dec;22(12):2556–2560. doi:10.1093/annonc/mdr037.
   PubMed Web of Science ®Google Scholar
• Sahra IB, Laurent K, Giuliano S, Larbret F, Ponzio G, Gounon P, Le Marchand-Brustel Y, Giorgetti-Peraldi S, Cormont M, Bertolotto C, et al. Targeting cancer cell metabolism: the combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells. Cancer Res. 2010 Mar 15;70(6):2465–2475. doi:10.1158/0008-5472.CAN-09-2782.
   PubMed Web of Science ®Google Scholar
• Sahra IB, Laurent K, Loubat A, Giorgetti-Peraldi S, Colosetti P, Auberger P, Tanti JF, Le Marchand-Brustel Y, Bost F. The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene. 2008 Jun 5;27(25):3576–3586. doi:10.1038/sj.onc.1211024.
   PubMed Web of Science ®Google Scholar
• Flavin R, Zadra G, Loda M. Metabolic alterations and targeted therapies in prostate cancer. J Pathol. 2011 Jan;223(2):283–294. doi:10.1002/path.2809.
   PubMed Web of Science ®Google Scholar
• Demir U, Koehler A, Schneider R, Schweiger S, Klocker H. Metformin anti-tumor effect via disruption of the MID1 translational regulator complex and AR downregulation in prostate cancer cells. BMC Cancer. 2014;14:52. doi:10.1186/1471-2407-14-52.
   PubMed Web of Science ®Google Scholar
• Wong YN, Ferraldeschi R, Attard G, De BJ. Evolution of androgen receptor targeted therapy for advanced prostate cancer. Nat Rev Clin Oncol. 2014 May 20;11:365–376. doi:10.1038/nrclinonc.2014.72.
   PubMed Web of Science ®Google Scholar
• Yu H, Yin L, Jiang X, Sun X, Wu J, Tian H, Gao X, He X, Medeiros R. Effect of metformin on cancer risk and treatment outcome of prostate cancer: a meta-analysis of epidemiological observational studies. PLoS One. 2014;9(12):e116327. doi:10.1371/journal.pone.0116327.
   PubMed Web of Science ®Google Scholar
• Heidegger I, Ofer P, Doppler W, Rotter V, Klocker H, Massoner P. Diverse functions of IGF/insulin signaling in malignant and noncancerous prostate cells: proliferation in cancer cells and differentiation in noncancerous cells. Endocrinology. 2012 Oct;153(10):4633–4643. doi:10.1210/en.2012-1348.
   PubMed Web of Science ®Google Scholar
• Chen YB, Chen Q, Wang Z, Zhou J. Insulin therapy and risk of prostate cancer: a systematic review and meta-analysis of observational studies. PLoS One. 2013;8(11):e81594. doi:10.1371/journal.pone.0081594.
   PubMed Web of Science ®Google Scholar
• Rieken M, Kluth LA, Xylinas E, Fajkovic H, Becker A, Karakiewicz PI, et al. Association of diabetes mellitus and metformin use with biochemical recurrence in patients treated with radical prostatectomy for prostate cancer. World J Urol. 2014 Aug;32(4):999–1005. doi:10.1007/s00345-013-1171-7.
   PubMed Web of Science ®Google Scholar
• Danzig MR, Kotamarti S, Ghandour RA, Rothberg MB, Dubow BP, Benson MC, Badani KK, McKiernan JM. Synergism between metformin and statins in modifying the risk of biochemical recurrence following radical prostatectomy in men with diabetes. Prostate Cancer Prostatic Dis. 2015 Mar;18(1):63–68. doi:10.1038/pcan.2014.47.
   PubMed Web of Science ®Google Scholar
• Rocha P, Morgan CJ, Templeton AJ, Pond GR, Naik G, Sonpavde G. Prognostic impact of C-reactive protein in metastatic prostate cancer: a systematic review and meta-analysis. Oncol Res Treat. 2014;37(12):772–776. doi:10.1159/000369545.
   PubMed Web of Science ®Google Scholar
• Matsuyama H, Shimabukuro T, Hara I, Kohjimoto Y, Suzuki K, Koike H, Uemura H, Hayashi T, Ueno M, Kodaira K, et al. Combination of hemoglobin, alkaline phosphatase, and age predicts optimal docetaxel regimen for patients with castration-resistant prostate cancer. Int J Clin Oncol. 2014 Oct;19(5):946–954. doi:10.1007/s10147-013-0638-2.
   PubMed Web of Science ®Google Scholar
• Zakikhani M, Dowling RJ, Sonenberg N, Pollak MN. The effects of adiponectin and metformin on prostate and colon neoplasia involve activation of AMP-activated protein kinase. Cancer Prev Res (Phila). 2008 Oct;1(5):369–375. doi:10.1158/1940-6207.CAPR-08-0081.
   PubMed Web of Science ®Google Scholar
• Tam WL, Weinberg RA. The epigenetics of epithelial-mesenchymal plasticity in cancer. Nat Med. 2013 Nov;19(11):1438–1449. doi:10.1038/nm.3336.
   PubMed Web of Science ®Google Scholar
• Nauseef JT, Henry MD. Epithelial-to-mesenchymal transition in prostate cancer: paradigm or puzzle? Nat Rev Urol 2011;Aug(8):428–439. doi:10.1038/nrurol.2011.85.
   Google Scholar
• Lehman DM, Lorenzo C, Hernandez J, Wang CP. Statin use as a moderator of metformin effect on risk for prostate cancer among type 2 diabetic patients. Diabetes Care. 2012 May;35(5):1002–1007. doi:10.2337/dc11-1829.
   PubMed Web of Science ®Google Scholar
• Preston MA, Riis AH, Ehrenstein V, Breau RH, Batista JL, Olumi AF, Mucci LA, Adami H-O, Sørensen HT. Metformin use and prostate cancer risk. Eur Urol. 2014 Dec;66(6):1012–1020. doi:10.1016/j.eururo.2014.04.027.
   PubMed Web of Science ®Google Scholar
• Spratt DE, Zhang C, Zumsteg ZS, Pei X, Zhang Z, Zelefsky MJ. Metformin and prostate cancer: reduced development of castration-resistant disease and prostate cancer mortality. Eur Urol. 2013 Apr;63(4):709–716. doi:10.1016/j.eururo.2012.12.004.
   PubMed Web of Science ®Google Scholar
• Kaushik D, Karnes RJ, Eisenberg MS, Rangel LJ, Carlson RE, Bergstralh EJ. Effect of metformin on prostate cancer outcomes after radical prostatectomy. Urol Oncol. 2014 Jan;32(1):43–47. doi:10.1016/j.urolonc.2013.05.005.
   PubMed Web of Science ®Google Scholar
• Allott EH, Abern MR, Gerber L, Keto CJ, Aronson WJ, Terris MK, Kane CJ, Amling CL, Cooperberg MR, Moorman PG, et al. Metformin does not affect risk of biochemical recurrence following radical prostatectomy: results from the SEARCH database. Prostate Cancer Prostatic Dis. 2013 Dec;16(4):391–397. doi:10.1038/pcan.2013.48.
   PubMed Web of Science ®Google Scholar
• Patel T, Hruby G, Badani K, Abate-Shen C, McKiernan JM. Clinical outcomes after radical prostatectomy in diabetic patients treated with metformin. Urology. 2010 Nov;76(5):1240–1244. doi:10.1016/j.urology.2010.03.059.
   PubMed Web of Science ®Google Scholar
• Deng D, Yang Y, Tang X, Skrip L, Qiu J, Wang Y, Zhang F. Association between metformin therapy and incidence, recurrence and mortality of prostate cancer: evidence from a meta-analysis. Diabetes Metab Res Rev. 2015 Feb 23;31:595–602. doi:10.1002/dmrr.v31.6.
   PubMed Web of Science ®Google Scholar
• Margel D, Urbach DR, Lipscombe LL, Bell CM, Kulkarni G, Austin PC, Fleshner N. Metformin use and all-cause and prostate cancer-specific mortality among men with diabetes. J Clin Oncol. 2013 Sep 1;31(25):3069–3075. doi:10.1200/JCO.2012.46.7043.
   PubMed Web of Science ®Google Scholar
• Kato H, Sekine Y, Furuya Y, Miyazawa Y, Koike H, Suzuki K. Metformin inhibits the proliferation of human prostate cancer PC-3 cells via the downregulation of insulin-like growth factor 1 receptor. Biochem Biophys Res Commun. 2015 May 22;461(1):115–121. doi:10.1016/j.bbrc.2015.03.178.
   PubMed Web of Science ®Google Scholar
• Ben Sahra I, Regazzetti C, Robert G, Laurent K, Le Marchand-Brustel Y, Auberger P, Tanti J-F, Giorgetti-Peraldi S, Bost F. Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1. Cancer Res. 2011 Jul 1;71(13):4366–4372. doi:10.1158/0008-5472.CAN-10-1769.
   PubMed Web of Science ®Google Scholar
• Li HX1, Gao JM1, Liang JQ1, Xi JM1, Fu M1, Wu YJ1. Vitamin D3 potentiates the growth inhibitory effects of metformin in DU145 human prostate cancer cells mediated by AMPK/mTOR signalling pathway. Clin Exp Pharmacol Physiol. 2015 Jun;42(6):711–717. doi:10.1111/1440-1681.12409.
   PubMed Web of Science ®Google Scholar
• Heidegger I, Kern J, Ofer P, Klocker H, Massoner P. Oncogenic functions of IGF1R and INSR in prostate cancer include enhanced tumor growth, cell migration and angiogenesis. Oncotarget. 2014 Apr 2;5. doi:10.18632/oncotarget.v5i9.
   Google Scholar
• Pollak M. The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat Rev Cancer. 2012 Mar;12(3):159–169. doi:10.1038/nrc3215.
   PubMed Web of Science ®Google Scholar
• Foretz M, Hébrard S, Leclerc J, Zarrinpashneh E, Soty M, Mithieux G, Sakamoto K, Andreelli F, Viollet B. Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J Clin Invest. 2010 Jul;120(7):2355–2369. doi:10.1172/JCI40671.
   PubMed Web of Science ®Google Scholar
• Griss T, Vincent EE, Egnatchik R, Chen J, Ma EH, Faubert B, Viollet B, DeBerardinis RJ, Jones RG, Green DR. Metformin antagonizes cancer cell proliferation by suppressing mitochondrial-dependent biosynthesis. PLoS Biol. 2015 Dec 1;13(12):e1002309. doi:10.1371/journal.pbio.1002309.
   PubMed Web of Science ®Google Scholar
• Kalender A, Selvaraj A, Kim SY, Gulati P, Brûlé S, Viollet B, Kemp BE, Bardeesy N, Dennis P, Schlager JJ, et al. Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner. Cell Metab. 2010 May 5;11(5):390–401. doi:10.1016/j.cmet.2010.03.014.
   PubMed Web of Science ®Google Scholar
• Wu L, Zhou B, Oshiro-Rapley N, Li M, Paulo JA, Webster CM, Mou F, Kacergis MC, Talkowski ME, Carr CE, et al. An ancient, unified mechanism for metformin growth inhibition in C. elegans and cancer. Cell. 2016 Dec 15;167(7):1705–1718.e13. doi:10.1016/j.cell.2016.11.055.
   PubMed Web of Science ®Google Scholar
• Memmott RM, Dennis PA. Akt-dependent and -independent mechanisms of mTOR regulation in cancer. Cell Signal. 2009 May;21(5):656–664. doi:10.1016/j.cellsig.2009.01.004.
   PubMed Web of Science ®Google Scholar
• Shi R, Berkel HJ, Yu H. Insulin-like growth factor-I and prostate cancer: a meta-analysis. Br J Cancer. 2001 Sep 28;85(7):991–996. doi:10.1038/sj.bjc.6691961.
   PubMed Web of Science ®Google Scholar
• Zhang J, Shen C, Wang L, Ma Q, Xia P, Qi M, Yang M, Han B. Metformin inhibits epithelial-mesenchymal transition in prostate cancer cells: involvement of the tumor suppressor miR30a and its target gene SOX4. Biochem Biophys Res Commun. 2014 Sep 26;452(3):746–752. doi:10.1016/j.bbrc.2014.08.154.
   PubMed Web of Science ®Google Scholar
• García-Pérez LE1, Alvarez M, Dilla T, Gil-Guillén V, Orozco-Beltrán D. Adherence to therapies in patients with type 2 diabetes. Diabetes Ther. 2013 Dec 4;4(2):175–194. doi:10.1007/s13300-013-0034-y.
   PubMed Web of Science ®Google Scholar
• Ahmad NS, Ramli A, Islahudin F, Paraidathathu T. Medication adherence in patients with type 2 diabetes mellitus treated at primary health clinics in Malaysia. Patient Prefer Adher. 2013 Jun 17;7:525–530. doi:10.2147/PPA.S44698.
   PubMed Web of Science ®Google Scholar